OTOTOXICITY — Comprehensive 50-Marks Answer

DEFINITION

CLASSIFICATION OF OTOTOXIC DRUGS

┌─────────────────────────────────────────────────────────────────┐
│                    OTOTOXIC AGENTS                               │
├───────────────────┬───────────────────┬─────────────────────────┤
│  ANTIBIOTICS      │  CHEMOTHERAPEUTICS│  MISCELLANEOUS          │
│                   │                   │                         │
│ • Aminoglycosides │ • Cisplatin        │ • Loop Diuretics        │
│   - Streptomycin  │ • Carboplatin      │   - Furosemide          │
│   - Gentamicin    │ • Nitrogen         │   - Ethacrynic acid     │
│   - Tobramycin    │   mustard          │   - Bumetanide          │
│   - Kanamycin     │                   │ • Antimalarials          │
│   - Amikacin      │                   │   - Quinine             │
│   - Neomycin      │                   │   - Chloroquine         │
│   - Netilmicin    │                   │ • Salicylates (Aspirin) │
│ • Erythromycin    │                   │ • Heavy metals          │
│                   │                   │ • Opioids (abuse)       │
└───────────────────┴───────────────────┴─────────────────────────┘

SGT KAN mnemonic (Vestibulotoxic → Cochleotoxic order) Streptomycin → Gentamicin → Tobramycin → Kanamycin → Amikacin → Neomycin

AMINOGLYCOSIDE OTOTOXICITY

Incidence

• Overall auditory toxicity: ~20%
• Vestibulotoxicity: ~15% — Cummings

Risk Factors

┌──────────────────────────────────────────────┐
│         RISK FACTORS FOR OTOTOXICITY         │
│                                              │
│  Patient Factors        Drug Factors         │
│  ───────────────        ────────────         │
│  • Renal dysfunction    • High cumulative    │
│  • Hepatic dysfunction    dose               │
│  • Bacteraemia          • Concomitant loop   │
│  • Fever                  diuretic           │
│  • Pre-existing HL      • Rapid infusion     │
│  • Advanced age         • Repeated courses   │
│  • A1555G mitochondrial                      │
│    12S rRNA mutation                         │
│  • Prior noise exposure                      │
└──────────────────────────────────────────────┘

Genetic Susceptibility

• The A1555G mutation in mitochondrial 12S rRNA makes human rRNA resemble bacterial rRNA — the drug's target.
• Found in ~17% of aminoglycoside-induced hearing loss patients.
• Particularly common in certain Chinese populations (~5–6% of population; responsible for 1/3 of aminoglycoside ototoxicity cases there).
• Only the auditory system (not vestibular) is sensitized by this mutation. — Cummings

PATHOPHYSIOLOGY / MECHANISMS OF OTOTOXICITY

1. Aminoglycoside — Mechanism

FLOW CHART: Aminoglycoside Ototoxicity Pathway
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━

Aminoglycoside systemic administration
         │
         ▼
Crosses into stria vascularis marginal cells
(via capillary circulation)
         │
         ▼
Enters endolymph
         │
         ▼
Enters hair cells via:
  ├── Mechanotransducer (MET) channels (primary)
  └── TRPA1 non-selective cation channels
         │
         ▼
Binds phosphatidylinositol on cell membrane
         │
         ▼
Chelates iron → generates Reactive Oxygen Species (ROS)
         │
         ▼
Targets intracellular organelles:
  ├── Mitochondria (primary target)
  ├── Endoplasmic reticulum
  └── Binds cytosolic rRNA
         │
         ▼
Outer Hair Cell (OHC) damage
  [Starts at INNER ROW of OHCs]
  [BASAL TURN first → apical progression]
         │
         ▼
→ High-frequency SNHL first → progresses to lower frequencies
→ Stria vascularis damage
         │
         ▼
IRREVERSIBLE hair cell loss

• ROS/RNS activate p53
• Activates caspase cascade: Caspase-8 → BID → BAX (translocates to mitochondria) → cytochrome-c leakage → Caspase-9 → Caspase-3/7 → Apoptosis — Cummings

2. Cisplatin — Mechanism

FLOW CHART: Cisplatin Ototoxicity Pathway
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━

Systemic cisplatin
         │
         ▼
Long-term retention in cochlea
(platinum detectable 60 days after last dose)
         │
         ▼
Activates cochlea-specific enzyme: NOX-3
(NADPH oxidase isoform unique to cochlea)
         │
         ▼
↑↑ Superoxide production
         │
         ▼
  ┌──────┴─────────┐
  │                │
  ▼                ▼
H₂O₂           + Nitric oxide → Peroxynitrite
  │                                    │
  ▼ (Fe²⁺ catalysed)                  ▼
Hydroxyl radical (•OH)          Nitrotyrosine in
  │                             auditory neurons
  ▼
Reacts with membrane
polyunsaturated fatty acids
  │
  ▼
4-Hydroxynonenal (highly toxic aldehyde)
  │
  ▼
↓ Glutathione in basal turn OHCs
  │
  ▼
Outer Hair Cell (OHC) apoptosis
[Basal turn OHCs most susceptible]
  │
  ▼
High-frequency permanent bilateral SNHL

COCHLEAR IMAGE — Anatomy of Damage

CLINICAL FEATURES

Cochleotoxicity (Hearing Loss)

• Bilateral, symmetric, sensorineural hearing loss
• High-frequency loss first (8 kHz, then extends downward)
• Permanent with aminoglycosides and cisplatin
• Preceded/accompanied by tinnitus (2–36% with cisplatin)
• May have ear pain (cisplatin)
• OAE abnormalities precede subjective hearing loss (early monitoring tool)

Vestibulotoxicity

• Oscillopsia (visual blurring during head movement)
• Gait imbalance, ataxia
• Symptoms worse in darkness
• Bilateral vestibular loss → difficult to compensate
• Recovery of oscillopsia from aminoglycosides is rarely complete
• Rotational testing: low-frequency responses affected first and most severely — Cummings

Salicylate Ototoxicity

• Tinnitus consistently at 6–8 g/day of aspirin
• Dose-dependent, reversible SNHL (resolves within 72 hours of stopping)
• Caloric responses also reduced
• Mechanism: prostaglandin inhibition → vasoconstriction of cochlear vasculature; inhibition of outer hair cell electromotility (prestin inhibition)

Loop Diuretic Ototoxicity

• Typically reversible, bilateral symmetric SNHL, sudden onset
• Block Na⁺-K⁺-2Cl⁻ symporter → alter strial metabolism → electrolyte imbalance in endolymph → ↓ endocochlear potential
• Greater with ethacrynic acid than furosemide
• Synergistic toxicity with aminoglycosides (most dangerous combination)

Quinine Ototoxicity

• Cinchonism: tinnitus, headache, nausea, disturbed vision
• Primarily cochleotoxic; usually transient
• Permanent loss at high doses or in sensitive patients
• Mechanism: reversible vasculitis and ischaemia of inner ear
• Degeneration in organ of Corti and stria vascularis

CISPLATIN — CLINICAL OTOTOXICITY DETAILS

• Young age (<5 years) or elderly
• Male children
• Cumulative dose >400 mg/m²
• Noise exposure
• Combination with other ototoxic drugs
• Nutritional depletion and anaemia
• Cranial irradiation (>48 Gy cochlear dose particularly dangerous in nasopharyngeal carcinoma)

• SNHL in >50% of patients; tinnitus in 7%
• Ultra-high frequency audiometry (>8 kHz) may show 100% incidence with high doses (150–225 mg/m²)
• Hearing loss at 8 kHz after 2 cycles predicts future need for hearing support
• Carboplatin: more ototoxic than initially thought; high-dose (2 g/m²) causes HL in 82% of children

MONITORING OF OTOTOXICITY

OTOTOXICITY MONITORING PROTOCOL
═══════════════════════════════

Pre-treatment:
  ├── Baseline pure-tone audiogram (250 Hz–8 kHz)
  ├── Ultra-high frequency audiometry (>8 kHz)
  ├── OAE (DPOAE/TEOAE)
  ├── ABR (in children/non-cooperative patients)
  └── Vestibular function tests (if applicable)

During treatment:
  ├── Repeat UHF audiometry after each 2 cycles (cisplatin)
  ├── Monitor serum drug levels (aminoglycosides — peak & trough)
  └── Monitor renal function (creatinine, GFR)

Post-treatment:
  ├── 6-weekly audiometry during treatment
  ├── 3-monthly for 1 year post completion
  └── Refer for hearing aids/cochlear implants if significant SNHL

GRADING (Chang/Brock/SIOP-Boston scale widely used):
  Grade 0 — No change from baseline
  Grade 1 — High frequency loss (>8 kHz) only
  Grade 2 — ≥20 dB at 4 kHz and above
  Grade 3 — ≥20 dB at 2 kHz and above
  Grade 4 — Requires hearing aids/cochlear implants

TOPICAL OTOTOXIC AGENTS

• Neomycin, gentamicin, tobramycin topical ear preparations are ototoxic if tympanic membrane is not intact
• With intact TM: no significant ototoxicity clinically
• With perforation/chronic OM: reduced permeability of inflamed round window, dilution by purulent fluid, and hyperaemic absorption reduce (but do not eliminate) toxicity
• AAO-HNS (2004) recommends against aminoglycoside topical use in the middle ear unless no alternative is available
• Intratympanic gentamicin is used therapeutically for chemical labyrinthectomy in Menière's disease — Cummings

PROTECTION AGAINST OTOTOXICITY

Against Aminoglycoside Ototoxicity:

• Salicylate pre-treatment (reduces aminoglycoside ototoxicity — paradoxically)
• Single daily dosing rather than multiple doses (reduces cochlear accumulation)
• Monitoring serum peak & trough levels
• Avoid concomitant loop diuretics

Against Cisplatin Ototoxicity — Antioxidants:

┌──────────────────────────────────────────────────────┐
│      OTOPROTECTIVE AGENTS (CISPLATIN)                │
├─────────────────────┬────────────────────────────────┤
│  Systemic           │  Intratympanic (preferred —    │
│                     │  avoids interference with      │
│                     │  antitumour effect)            │
├─────────────────────┼────────────────────────────────┤
│ • N-acetylcysteine  │ • Dexamethasone               │
│ • α-Tocopherol      │ • siRNA against NOX-3         │
│ • Lipoic acid       │ • Sodium thiosulfate           │
│ • D-methionine      │   (6 hrs after cisplatin)     │
│ • Amifostine        │                                │
│ • Sodium thiosulfate│                                │
│ • Ebselen           │                                │
└─────────────────────┴────────────────────────────────┘

RADIATION OTOTOXICITY

• Head and neck/skull base irradiation causes SNHL
• Cochlear dose >48 Gy significantly increases risk (especially with concomitant cisplatin — nasopharyngeal carcinoma)
• IMRT (Intensity-Modulated Radiotherapy): Only 13% with grade 3/4 HL vs 64% with conventional RT
• Mechanism: strial damage, spiral ganglion degeneration, cochlear fibrosis — Cummings

HYDROCODONE ABUSE OTOTOXICITY

• Rapidly progressive bilateral SNHL (12 cases reported)
• Unilateral in 4/12 cases; vestibular symptoms in 1/12
• Steroid-resistant — does not respond to corticosteroids
• Cochlear implant successful (7/8 cases)
• Mechanism: μ-type opioid receptors in spiral and Scarpa's ganglia; δ- and κ-type receptors in hair cells — Cummings

RECENT ADVANCES

╔══════════════════════════════════════════════════════════════════╗
║                    RECENT ADVANCES IN OTOTOXICITY               ║
╠══════════════════════════════════════════════════════════════════╣
║                                                                  ║
║  1. MOLECULAR TARGETS:                                           ║
║     • TRPA1 channel blockade prevents AG hair cell uptake        ║
║     • siRNA against NOX-3 prevents cisplatin ototoxicity         ║
║     • TRPV1–NOX-3–STAT1 cascade identified in cisplatin HL      ║
║     • KSR1 scaffold protein — MAPK pathway activation in OHC    ║
║                                                                  ║
║  2. GENETIC TESTING:                                             ║
║     • A1555G mitochondrial 12S rRNA mutation screening           ║
║       before aminoglycoside therapy                              ║
║     • Multiple pharmacogenetic associations found for            ║
║       cisplatin susceptibility                                   ║
║                                                                  ║
║  3. NOVEL DRUG DELIVERY:                                         ║
║     • Intratympanic drug delivery (avoids systemic effects)      ║
║     • Cisplatin nanoparticles with localised cochlear delivery   ║
║     • Hydrogel-based round window membrane drug delivery         ║
║                                                                  ║
║  4. BIOMARKERS:                                                  ║
║     • UHF audiometry + DPOAEs as early biomarkers               ║
║     • Long-term platinum retention in cochlea demonstrated       ║
║       (explains delayed-onset hearing loss post-cisplatin)      ║
║                                                                  ║
║  5. OTOPROTECTION:                                               ║
║     • Phase 3 trial: Sodium thiosulfate protects vs cisplatin   ║
║     • AMPHIA trial ongoing (D-methionine)                        ║
║     • CPI-455 (histone demethylase inhibitor) — preserves        ║
║       hair cells and spiral ganglion neurons post-cisplatin      ║
║                                                                  ║
║  6. NEW AGENTS:                                                  ║
║     • Apramycin (veterinary AG) — significant antimicrobial      ║
║       efficacy with claimed minimal ototoxicity (ongoing study) ║
║     • ERK pathway inhibitors (gentamicin-induced OHC damage)    ║
║                                                                  ║
╚══════════════════════════════════════════════════════════════════╝

SUMMARY DIAGRAM — OVERALL OTOTOXICITY FRAMEWORK

                    OTOTOXIC AGENT
                         │
           ┌─────────────┴──────────────┐
           │                            │
       COCHLEA                     VESTIBULE
    (Cochleotoxicity)           (Vestibulotoxicity)
           │                            │
    Outer Hair Cells               Type I Hair Cells
    (Basal turn first)             (Crista ampullaris,
    Stria vascularis               Macula utriculi/sacculi)
           │                            │
    SNHL (High freq first)        Oscillopsia, Ataxia,
    Tinnitus                      Dizziness, Imbalance
           │                            │
    ┌──────┴──────────────────────┐     │
    │     MECHANISMS              │     │
    │  • ROS/RNS generation       │     │
    │  • Iron chelation           │     │
    │  • Mitochondrial damage     │     │
    │  • Apoptotic cascade        │     │
    │    (Caspase 3/7/8/9)        │     │
    │  • NOX-3 activation         │     │
    │    (cisplatin only)         │     │
    └─────────────────────────────┘     │
           │                            │
    MONITORING                   MONITORING
    Audiogram (UHF)             Caloric test
    OAE, ABR                    vHIT, VEMP
    Drug levels                 Rotational chair
           │
    PREVENTION / TREATMENT
    ├── Antioxidants (NAC, α-tocopherol, D-methionine)
    ├── Sodium thiosulfate (cisplatin)
    ├── Avoid nephrotoxic drugs concurrently
    ├── Single daily dosing (aminoglycosides)
    ├── Genetic screening (A1555G mutation)
    ├── Intratympanic dexamethasone
    └── Hearing aids / Cochlear implants (if severe)

QUICK REFERENCE TABLE — IMPORTANT FACTS FOR EXAMS

REFERENCES (Textbook Sources)

1. Cummings Otolaryngology Head and Neck Surgery (6th ed., Flint et al.) — Chapter on Ototoxicity: pp. 3010–3025
2. KJ Lee's Essential Otolaryngology (11th ed.) — Ototoxicity section, pp. 226–227
3. Goodman & Gilman's The Pharmacological Basis of Therapeutics — Aminoglycoside and loop diuretic ototoxicity
4. Dhingra's Diseases of Ear, Nose and Throat — Ototoxic drugs (standard RGUHS reference)
5. Hazarika's Textbook of ENT — Drug-induced hearing loss
6. Scott Brown's Otorhinolaryngology Head and Neck Surgery — Inner ear pharmacology and ototoxicity
7. Zakir Hussain's ENT — Ototoxicity (Indian PG reference)
8. Stell & Maran's Head and Neck Surgery — Relevant otology section

Key Exam Points to Remember for RGUHS 50-Marks:

1. Define → Classify (with table) → Mechanism (flowchart for AG + cisplatin separately) → Clinical features (cochleo vs vestibulo) → Monitoring protocol → Protection/treatment → Recent advances
2. The mnemonic SGT KAN for aminoglycoside vestibulo→cochleotoxic order
3. A1555G mutation = genetic predisposition to AG ototoxicity
4. NOX-3 = cochlea-specific enzyme activated by cisplatin
5. Sodium thiosulfate = most promising otoprotectant (Phase 3 trial positive)
6. No FDA-approved drug currently exists to prevent cisplatin ototoxicity
7. Loop diuretics + aminoglycosides = most dangerous synergistic combination